

ForPatients

by Roche

Neoplasms Solid Tumors Tumor

An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)

Trial Status

Active, not recruiting

Trial Runs In

1 Countries

Trial Identifier

NCT05112965 YO42713

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This is an open-label, multicenter, non-randomized extension study. Participants receiving atezolizumab monotherapy or atezolizumab combined with other agent(s) or comparator agent(s) in a Genentech or Roche-sponsored study (the parent study), who are eligible to continue treatment and do not have access to the study treatment locally, continue to receive study treatment in this extension study.

Hoffmann-La Roche

Sponsor

Phase 3

Phase

NCT05112965 YO42713

Trial Identifiers

Eligibility Criteria:

Gender

All

Age

≥ 18 Years

Healthy Volunteers

No
